Ixazomib
Proteasome Inhibitor
DB09570
Approved Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
0
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Ixazomib is an N-capped dipeptidyl leucine boronic acid which reversibly inhibits the CT-L proteolytic (β5) site of the 20S proteasome. At higher concentrations, ixazomib also seems to inhibit the proteolytic β1 and β2 subunits and to induce accumulation of ubiquitinated proteins.
Details
DrugBank ID
DB09570 ↗
Approval Date
2015-11-20
Molecular Weight
361.03 g/mol
Drug Class
Proteasome Inhibitor
ATC Codes
L01XX50
Synonyms
—
PubChem
CID: 25183872 ↗
ChEMBL
CHEMBL2141296 ↗
SMILES
[H][C@@](CC(C)C)(N=C(O)CN=C(O)C1=C(Cl)C=CC(Cl)=C1)B(O)O
ADMET Profile
Computing properties…
Drug References (DrugBank)